Neo-adjuvant Capecitabine Chemotherapy in Women with Newly Diagnosed Locally Advanced Breast Cancer in a Resource-poor Setting (Nigeria): Efficacy and Safety in a Phase II Feasibility Study

Breast Journal

Volumn 19, Issue 5, 2013, Pages 470-477

  Arowolo, Olukayode A ^a   Njiaju, Uchenna O ^b   Ogundiran, Temidayo O ^c   Abidoye, Oyewale ^b   Lawal, Olukayode O ^a   Obajimi, Millicent ^c   Adetiloye, Adebayo V ^a   Im, Hae K ^d   Akinkuolie, Akinbolaji A ^a   Oluwasola, Abideen ^c   Adelusola, Kayode ^a   Kayode, Adesunkanmi A ^a   Agbakwuru, Augustine E ^a   Oduntan, Helen ^e   Babalola, Chinedum P ^c   Fleming, Gini ^b   Olopade, Olusola C ^b   Falusi, Adeyinka Gladys ^c   Durosinmi, Muheez A ^a   Olopade, Olufunmilayo I ^b  

^a OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF IBADAN   (Nigeria)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

capecitabine; clinical response; locally advanced breast cancer; Nigeria; resource poor country

Indexed keywords

CAPECITABINE;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEMALE; HAND FOOT SYNDROME; HUMAN; MAMMOGRAPHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NIGERIA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; SORE THROAT; THROMBOCYTOPENIA; TREATMENT DURATION;

CAPECITABINE; CLINICAL RESPONSE; LOCALLY ADVANCED BREAST CANCER; NIGERIA; RESOURCE-POOR COUNTRY;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NIGERIA;

EID: 84884906008     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12149     Document Type: Article

References (39)

1. Adebamowo CA, Ajayi OO,. Breast cancer in Nigeria. West Afr J Med 2000; 19: 179-91.
2. Okobia MN, Osime U,. Clinicopathological study of carcinoma of the breast in Benin City. Afr J Reprod Health 2001; 5: 56-62.
3. Adesunkanmi ARK, Lawal OO, Adelusola KA, Durosimi MA,. The severity, outcome and challenges of breast cancer in Nigeria. Breast 2006; 15: 399-409.
4. Layman RM, Thomas DG, Griffith KA, et al,. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Clin Cancer Res 2007; 13: 4092-7.
5. Morris JA, Kelly JF,. Multiple bilateral breast adenomata in identical adolescent Negro twins. Histopathology 1982; 6: 539-47.
6. Anyanwu SN,. Survival following treatment of primary breast cancer in eastern Nigeria. East Afr Med J 2000; 77: 539-43.
7. Chiedozi LC,. Breast carcinoma in young Nigerian women. Trop Geogr Med 1984; 36: 249-53.
8. Chiedozi LC,. Rapidly progressing breast cancer in Nigeria. Eur J Surg Oncol 1987; 13: 505-9.
9. El Saghir NS, Eniu A, Carlson RW,. Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries. Cancer 2008; 113 (8 Suppl): 2315-24.
10. Eniu A, Carlson RW, Aziz Z, et al,. Breast cancer in limited-resource countries: treatment and allocation of resources. Breast J 2006; 12 (Suppl. 1): S38-53.
11. Rastogi P, Anderson SJ, Bear HD, et al,. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-85.
12. Arowolo OA, Akinkuolie AA, Lawal OO, Alatise OI, Salako AA, Adisa AO,. The impact of neoadjuvant chemotherapy on patients with locally advanced breast cancer in a Nigerian semiurban teaching hospital: a single-center descriptive study. World J Surg 2000; 34: 1771-8.
13. Valero VV, Buzdar AU, Hortobagyi GN,. Locally advanced breast cancer. Oncologist 1996; 1: 8-17.
14. Valero V, Buzdar AU, McNeese M, Singletary E, Hortobaygi GN,. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer 2002; 3 (Suppl. 2): S63-8.
15. Stearns V, Singh B, Tsangaris T, et al,. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 2003; 9: 124-33.
16. National Cancer Institute. Common Toxicity Criteria Manual version 2.0. cancer Therapy Evaluation Programm 1999: 1-27.
17. William BE,. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 2006; 11: 325-35.
18. Lee SH, Lee J, Park J,. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncologist 2004; 21: 223-31.
19. Pierga JY, Fumoleau P, Brewer Y, et al,. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. Breast Cancer Res Treat 2004; 88: 117-29.
20. O'Shaughnessy JA, Blum JL,. Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer. Clin Breast Cancer 2006; 7: 42-50.
21. Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al,. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14: 1227-33.
22. Saeki T, Takashima S,. Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer. Breast Cancer 2004; 11: 116-20.
23. Figgitt DP, Wiseman LR,. Docetaxel: an update of its use in advanced breast cancer. Drugs 2000; 59: 621-51.
24. Bear HD, Anderson S, Brown A, et al,. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-74.
25. Heys SD, Hutcheon AW, Sarkar TK, et al,. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002; 3 (Suppl. 2): S69-74.
26. Talbot DC, Moiseyenko V, Van Belle S, et al,. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86: 1367-72.
27. Greil R, Moik M, Reitsamer R, et al,. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: efficacy and safety in a phase II pilot study. Eur J Surg Oncol 2009; 35: 1048-54.
28. Jinno H, Sakata M, Hayashida T, et al,. A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer. Ann Oncol 2000; 21: 1262-6.
29. Madjar H, Ladner HA, Sauerbrei W, Oberstein A, Prompeler H, Pfleiderer A,. Preoperative staging of breast cancer by palpation, mammography and high-resolution ultrasound. Ultrasound Obstet Gynecol 1993; 3: 185-90.
30. Kald BA, Boiesen P, Ronnow K, Jonsson PE, Bisgaard T,. Preoperative assessment of small tumours in women with breast cancer. Scand J Surg 2005; 94: 15-20.
31. Lorendo V, Bazzocchi D, Del Frate C, et al,. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 2004; 14: 1371-9.
32. Huber S, Medl M, Vesely M, Czermbierk H, Zunna I, Delorme S,. Ultrasonographic tissue characterization in monitoring tumor response to neoadjuvant chemotherapy in locally advanced breast cancer. J Ultrasound Med 2000; 19: 677-86.
33. Bruno D, Fornage MD, Olivier T, Michel M,. Clinical, mammographic, and sonographic determination of preoperative breast cancer size. Cancer 1987; 60: 765-71.
34. Moneer M, El-Didi M, Khaled H,. Breast conservative surgery: is it appropriate for locally advanced breast cancer following downstaging by neoadjuvant chemotherapy?: A pathological assessment. Breast 1998; 319: 00.
35. Cocconi G, Dil Blasio B, Alberti G, Biagni G, Botti E, Peracchia G,. Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res 1984; 4: 309-13.
36. Wenzel C, Bartsch R, Locker GJ, et al,. Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer. Anticancer Drugs 2005; 16: 441-5.
37. Oshaughnessy JA, Blum J, Moiseyenko V, et al,. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12: 1247-54.
38. Cassidy J, Twelves C, Van Custen E,. First-line oral capecitabine therapy in metastatic colorectal cancer a favourable safety profile compared with intravenous 5-Fluorouracil/Leucovorin. Ann Oncol 2003; 14: 1735-43.
39. Vancustem E, Findlay M, Osterwald B,. Capecitabine, an oral fluoropyrimidine carbamate with substantive activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18: 1337-45.